These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17983891)

  • 1. Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
    Carson CC
    Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phosphodiesterase 5 inhibition in erectile dysfunction. Long-term administration without therapeutic advantage].
    MMW Fortschr Med; 2009 Jan; 151(1-2):50-1. PubMed ID: 19227645
    [No Abstract]   [Full Text] [Related]  

  • 10. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
    Patel MD; Katz SD
    Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
    Fabbri A; Aversa A
    Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
    Hellstrom WJ
    Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.